Literature DB >> 16610361

Protein aggregation as a cause for disease.

T Scheibel1, J Buchner.   

Abstract

The ability of proteins to fold into a defined and functional conformation is one of the most fundamental processes in biology. Certain conditions, however, initiate misfolding or unfolding of proteins. This leads to the loss of functional protein or it can result in a wide range of diseases. One group of diseases, which includes Alzheimer's, Parkinson's, Huntington's disease, and the transmissible spongiform encephalopathies (prion diseases), involves deposition of aggregated proteins. Normally, such protein aggregates are not found in properly functioning biological systems, because a variety of mechanisms inhibit their formation. Understanding the nature of these protective mechanisms together with the understanding of factors reducing or deactivating the natural protection machinery will be crucial for developing strategies to prevent and treat these disastrous diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16610361     DOI: 10.1007/3-540-29717-0_9

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  9 in total

1.  Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation.

Authors:  Tiago Fleming Outeiro; Jochen Klucken; Katherine E Strathearn; Fang Liu; Paul Nguyen; Jean-Christophe Rochet; Bradley T Hyman; Pamela J McLean
Journal:  Biochem Biophys Res Commun       Date:  2006-10-26       Impact factor: 3.575

Review 2.  The Pathogenic Role of Ganglioside Metabolism in Alzheimer's Disease-Cholinergic Neuron-Specific Gangliosides and Neurogenesis.

Authors:  Toshio Ariga
Journal:  Mol Neurobiol       Date:  2017-01       Impact factor: 5.590

3.  A folded and functional protein domain in an amyloid-like fibril.

Authors:  Mirko Sackewitz; Sabrina von Einem; Gerd Hause; Michael Wunderlich; Franz-Xaver Schmid; Elisabeth Schwarz
Journal:  Protein Sci       Date:  2008-04-18       Impact factor: 6.725

4.  Alternative assembly pathways of the amyloidogenic yeast prion determinant Sup35-NM.

Authors:  Simone Hess; Susan L Lindquist; Thomas Scheibel
Journal:  EMBO Rep       Date:  2007-11-02       Impact factor: 8.807

5.  Absence of ataxin-3 leads to enhanced stress response in C. elegans.

Authors:  Ana João Rodrigues; Andreia Neves-Carvalho; Andreia Teixeira-Castro; Anne Rokka; Garry Corthals; Elsa Logarinho; Patrícia Maciel
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

6.  Diabetes Drug Discovery: hIAPP1-37 Polymorphic Amyloid Structures as Novel Therapeutic Targets.

Authors:  Isaac Fernández-Gómez; Marquiza Sablón-Carrazana; Alberto Bencomo-Martínez; Guadalupe Domínguez; Reyna Lara-Martínez; Nelly F Altamirano-Bustamante; Luis Felipe Jiménez-García; Karina Pasten-Hidalgo; Rosa Angélica Castillo-Rodríguez; Perla Altamirano; Suchitil Rivera Marrero; Cristina Revilla-Monsalve; Peter Valdés-Sosa; Fabio Salamanca-Gómez; Eulalia Garrido-Magaña; Chryslaine Rodríguez-Tanty; Myriam M Altamirano-Bustamante
Journal:  Molecules       Date:  2018-03-19       Impact factor: 4.411

7.  Guanidine-HCl dependent structural unfolding of M-crystallin: fluctuating native state like topologies and intermolecular association.

Authors:  Ravi Pratap Barnwal; Geetika Agarwal; Kandala V R Chary
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

8.  Random amino acid mutations and protein misfolding lead to Shannon limit in sequence-structure communication.

Authors:  Andreas Martin Lisewski
Journal:  PLoS One       Date:  2008-09-01       Impact factor: 3.240

9.  Drug Development in Conformational Diseases: A Novel Family of Chemical Chaperones that Bind and Stabilise Several Polymorphic Amyloid Structures.

Authors:  Marquiza Sablón-Carrazana; Isaac Fernández; Alberto Bencomo; Reyna Lara-Martínez; Suchitil Rivera-Marrero; Guadalupe Domínguez; Rafaela Pérez-Perera; Luis Felipe Jiménez-García; Nelly F Altamirano-Bustamante; Massiel Diaz-Delgado; Fernand Vedrenne; Lina Rivillas-Acevedo; Karina Pasten-Hidalgo; María de Lourdes Segura-Valdez; Sergio Islas-Andrade; Eulalia Garrido-Magaña; Alejandro Perera-Pintado; Anaís Prats-Capote; Chryslaine Rodríguez-Tanty; Myriam M Altamirano-Bustamante
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.